MCHM3001 · From Molecules to Therapeutics
Preclinical Toxicology
Lecture 22 of MCHM3001 covers the safety testing that stands between a candidate and first-in-human dosing: the history and meaning of LD50, cytochrome-P450 inhibition and induction (drug-drug interactions), the repeat-dose, reproductive and genotoxicity studies, and how a safety margin is established. The examinable core is interpreting genotoxicity and metabolism data and reasoning about safety margins. It appears in the final exam.
What this chapter covers
- 01History and meaning of LD50 (Trevan 1927, dose lethal to 50%); now superseded by mechanistic safety approaches
- 02Preclinical study list: repeat-dose, genotoxicity, carcinogenicity, reproductive and safety-pharmacology studies feeding CTD Module 4
- 03CYP inhibition (competitive/non-competitive; ketoconazole for 3A4, quinidine for 2D6) and induction (AhR, CAR, PXR; rifampicin) as drug-drug-interaction sources
- 04Study design: two mammalian species (one non-rodent); acute vs repeat-dose (chronic to MTD)
- 05Reproductive toxicity: placental transfer and milk excretion; timing stages; thalidomide binding cereblon (E3 ligase) in a danger window
- 06Genotoxicity (ICH S2): the Ames test (±S9 activation), the mouse-lymphoma Tk assay and the in-vivo micronucleus assay
- 07Carcinogenicity: two-year rodent studies at low/medium/high (MTD) doses
- 08Establishing a safety margin before first-in-human trials
Interpreting an Ames test that needs metabolic activation
- +1(a) S9 supplies the metabolic enzymes (chiefly CYP450s) that the bacteria lack, mimicking mammalian Phase I metabolism. A positive result only with S9 means mutagenicity appears only after the compound is metabolised.
- +1(b) Therefore the parent molecule is not directly mutagenic; a reactive metabolite generated by S9 metabolism is the likely genotoxin (bioactivation).
- +1(c) Confirm and characterise under ICH S2: run an in-vitro mammalian assay such as the mouse-lymphoma Tk assay (also ±S9) and an in-vivo assay such as the bone-marrow micronucleus test to see whether the hazard occurs in a whole animal.
- +1(c cont.) Feed the medicinal chemistry back: if a reactive metabolite is confirmed, redesign to block the bioactivation (e.g. remove or shield the vulnerable group), because a genotoxic metabolite is a serious liability for progression.
Key terms
- LD50
- The dose lethal to 50% of a test population (Trevan, 1927); historically a crude acute-toxicity measure, now superseded by mechanistic safety-assessment approaches for drugs.
- CYP inhibition / induction
- Drug-drug-interaction mechanisms: an inhibitor (e.g. ketoconazole for CYP3A4) slows metabolism of co-dosed drugs, while an inducer (e.g. rifampicin, via xenosensors AhR/CAR/PXR) speeds it up by increasing enzyme levels.
- Ames test
- A bacterial reverse-mutation assay using histidine-auxotroph Salmonella strains, run with and without the S9 rat-liver fraction; reversion to histidine independence signals mutagenicity, and the S9 requirement reveals metabolic activation.
- S9 fraction
- A rat-liver preparation supplying metabolic (mainly CYP) enzymes in an in-vitro genotoxicity assay; a compound positive only with S9 is bioactivated to a genotoxic metabolite.
- Micronucleus assay
- An in-vivo genotoxicity test (typically bone marrow) that detects chromosome damage as micronuclei; used to confirm whether an in-vitro hazard occurs in a whole animal.
- Safety margin
- The gap between the exposure shown to cause no adverse effect in animals and the intended human exposure (e.g. via the exposure ratio at the NOAEL), used to justify a safe first-in-human dose.
Preclinical Toxicology FAQ
What does it mean if a compound is Ames-positive only with S9?
The S9 fraction adds mammalian metabolic enzymes (mainly CYP450s) that the test bacteria do not have. If the compound is mutagenic only when S9 is present, then it is not the parent molecule that damages DNA but a reactive metabolite produced by metabolism — a process called bioactivation. That distinction matters, because you may be able to redesign the molecule to block the metabolic step that creates the genotoxin.
Why did LD50 fall out of use for drug safety?
LD50 — the dose that kills half a test population — was a crude single number that used many animals and told you little about mechanism or about the sub-lethal, chronic and reproductive effects that actually matter for a medicine. Modern preclinical toxicology instead uses mechanistic, repeat-dose, genotoxicity, carcinogenicity and reproductive studies to characterise the real hazard and to set a safety margin, so LD50 is now historical context rather than a drug-safety endpoint.
How can CYP enzymes cause drug-drug interactions?
Through inhibition and induction. An inhibitor (for example ketoconazole on CYP3A4) blocks the metabolism of a co-administered drug, raising its levels and toxicity risk. An inducer (for example rifampicin, acting through xenosensors such as PXR) increases the amount of enzyme, speeding metabolism and lowering a co-dosed drug's exposure and effect. Predicting these interactions is a core part of preclinical safety assessment.
Can AI help me with the preclinical-toxicology material in MCHM3001?
Yes. Sia can help you interpret genotoxicity results (including the S9 activation logic), contrast CYP inhibition with induction, explain the preclinical study battery and how a safety margin is set, and place the toxicology data in CTD Module 4. It explains the reasoning and checks your interpretation; it does not do graded assessment for you, and University of Sydney academic-integrity rules apply.
Exam move
Focus on interpretation, because that is how this chapter is examined. Master the S9 logic in the Ames test (positive only with S9 means a bioactivated metabolite) and be able to name the confirmatory assays (mouse-lymphoma Tk, in-vivo micronucleus). Keep CYP inhibition versus induction straight with one example each (ketoconazole inhibits, rifampicin induces) and understand why each changes a co-dosed drug's exposure. Hold the preclinical study list and the idea of a safety margin (linking back to the exposure ratio and CTD Module 4) ready as short-answer material. When a data-interpretation question stumps you, ask Sia to walk through the inference and then flip the scenario so you can practise the opposite conclusion.
Working through Preclinical Toxicology in MCHM3001? Sia is AskSia’s AI Chemistry tutor — ask any MCHM3001 Preclinical Toxicology question and get a clear, step-by-step explanation grounded in how MCHM3001 is taught and assessed. Read this chapter free, then take your hardest questions to Sia.
